Episodic Neurological Dysfunction in X-Linked Charcot-Marie-Tooth Disease: Expansion of the Phenotypic and Genetic Spectrum
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose X-linked Charcot-Marie-Tooth disease type 1 (CMTX1) is characterized by peripheral neuropathy with or without episodic neurological dysfunction. We performed clinical, neuropathological, and genetic investigations of a series of patients with mutations of the gap-junction beta-1 gene (GJB1) to extend the phenotypic and genetic description of CMTX1. Methods Detailed clinical evaluations, sural nerve biopsy, and genetic analysis were applied to patients with CMTX1. Results We collected 27 patients with CMTX1 with GJB1 mutations from 14 unrelated families. The age at onset (AAO) was 20.9±12.2 years (mean±standard deviation; range, 2–45 years). Walking difficulties, weakness in the legs, and pes cavus were common initial symptoms. Compared with female patients, males tended to have a younger AAO (males vs. females= 15.4±9.6 vs. 32.0±8.8 years, p=0.002), a longer disease course (16.8±16.1 vs. 5.5±3.8 years, p=0.034), and more-severe electrophysiological results. Besides peripheral neuropathy, six of the patients had special episodic central nervous system (CNS) evidence from symptoms, signs, and/or reversible white-matter lesions. Neuropathology revealed the loss of large myelinated fibers, increased number of regenerated axon clusters with abnormally thin myelin sheaths, and excessively folded myelin. Genetic analysis identified 14 GJB1 variants, 6 of which were novel. Conclusions These findings expand the phenotypic and genetic spectrum of CMTX1. Although CMTX1 was found to have high phenotypic and CNS involvement variabilities, detailed neurological examinations and nerve conduction studies will provide critical clues for accurate diagnoses. Further exploration of the underlying mechanisms of connexin 32 involvement in neuropathy or CNS dysfunction is warranted to develop promising therapies.
Abstract
Background and Purpose X-linked Charcot-Marie-Tooth disease type 1 (CMTX1) is characterized by peripheral neuropathy with or without episodic neurological dysfunction. We performed clinical, neuropathological, and genetic investigations of a series of patients with mutations of the gap-junction beta-1 gene (GJB1) to extend the phenotypic and genetic description of CMTX1. Methods Detailed clinical evaluations, sural nerve biopsy, and genetic analysis were applied to patients with CMTX1. Results We collected 27 patients with CMTX1 with GJB1 mutations from 14 unrelated families. The age at onset (AAO) was 20.9±12.2 years (mean±standard deviation; range, 2–45 years). Walking difficulties, weakness in the legs, and pes cavus were common initial symptoms. Compared with female patients, males tended to have a younger AAO (males vs. females= 15.4±9.6 vs. 32.0±8.8 years, p=0.002), a longer disease course (16.8±16.1 vs. 5.5±3.8 years, p=0.034), and more-severe electrophysiological results. Besides peripheral neuropathy, six of the patients had special episodic central nervous system (CNS) evidence from symptoms, signs, and/or reversible white-matter lesions. Neuropathology revealed the loss of large myelinated fibers, increased number of regenerated axon clusters with abnormally thin myelin sheaths, and excessively folded myelin. Genetic analysis identified 14 GJB1 variants, 6 of which were novel. Conclusions These findings expand the phenotypic and genetic spectrum of CMTX1. Although CMTX1 was found to have high phenotypic and CNS involvement variabilities, detailed neurological examinations and nerve conduction studies will provide critical clues for accurate diagnoses. Further exploration of the underlying mechanisms of connexin 32 involvement in neuropathy or CNS dysfunction is warranted to develop promising therapies.
참고문헌 (36)
- Barreto LC, "Epidemiologic study of Charcot-Marie-Tooth disease : a systematic review", Neuroepidemiology, 46, pp.157~165 (2016)
- Klein CJ, "Charcot-Marie-Tooth Disease and other hereditary neuropathies", Continuum(Minneap Minn), 26, pp.1224~1256 (2020)
- Pareyson D, "New developments in Charcot–Marie–Tooth neuropathy and related diseases", Curr Opin Neurol, 30, pp.471~480 (2017)
- Beijer D, "The expanding genetic landscape of hereditary motor neuropathies", Brain, 143, pp.3540~3563 (2020)
- Saporta AS, "Charcot-Marie-Tooth disease subtypes and genetic testing strategies", Ann Neurol, 69, pp.22~33 (2011)
- Murphy SM, "Charcot-Marie-Tooth disease : frequency of genetic subtypes and guidelines for genetic testing", J Neurol Neurosurg Psychiatry, 83, pp.706~710 (2012)
- Wang Y, "A review of X-linked Charcot-Marie-Tooth disease", J Child Neurol, 31, pp.761~772 (2016)
- Abrams CK, "GJB1-associated X-linked Charcot-Marie-Tooth disease, a disorder affecting the central and peripheral nervous systems", Cell Tissue Res, 360, pp.659~673 (2015)
- Kleopa KA, "Connexins, gap junctions and peripheral neuropathy", Neurosci Lett, 596, pp.27~32 (2015)
- Bortolozzi M, "What’s the function of connexin 32 in the peripheral nervous system?", Front Mol Neurosci, 11, pp.227~ (2018)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Yuan JH, "Genetic and phenotypic profile of 112 patients with Xlinked Charcot-Marie-Tooth disease type 1", Eur J Neurol, 25, pp.1454~1461 (2018)
- Tsai PC, "Clinical and biophysical characterization of 19 GJB1 mutations", Ann Clin Transl Neurol, 3, pp.854~865 (2016)
- Liu X, "Cross-sectional study in a large cohort of Chinese patients with GJB1 gene mutations", Front Neurol, 11, pp.690~ (2020)
- Panosyan FB, "Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease(CMTX1)", Neurology, 89, pp.927~935 (2017)
- Kleopa KA, "Molecular genetics of X-linked Charcot-Marie-Tooth disease", Neuromolecular Med, 8, pp.107~122 (2006)
- Pareyson D, "A multicenter retrospective study of Charcot-Marie-Tooth disease type 4B(CMT4B)associated with mutations in myotubularin-related proteins(MTMRs)", Ann Neurol, 86, pp.55~67 (2019)
- Horn M, "Myelin is dependent on the Charcot-Marie-Tooth type 4H disease culprit protein FRABIN", FGD4 in Schwann cells, 2012, pp.135(Pt 12), 3567~3583
- Tian D, "Systematic review of CMTX1 patients with episodic neurological dysfunction", Ann Clin Transl Neurol, 8, pp.213~223 (2021)
- Taylor RA, "The CNS phenotype of X-linked Charcot-Marie-Tooth disease : more than a peripheral problem", Neurology, 61, pp.1475~1478 (2003)
- Siskind C, "Persistent CNS dysfunction in a boy with CMT1X", J Neurol Sci, 279, pp.109~113 (2009)
- Wen Q, "The electrophysiological features in Xlinked charcot-marie-tooth disease with transient central nervous system deficits", Front Neurol, 9, pp.461~ (2018)
- Bergoffen J, "Connexin mutations in X-linked Charcot-Marie-Tooth disease", Science, 262, pp.2039~2042 (1993)
- Nakase T, "Gap junctions and neurological disorders of the central nervous system", Biochim Biophys Acta, 1662, pp.149~158 (2004)
- Willecke K, "Structural and functional diversity of connexin genes in the mouse and human genome", Biol Chem, 383, pp.725~737 (2002)
- Liu L, "Phenotypes and cellular effects of GJB1 mutations causing CMT1X in a cohort of 226Chinese CMT families", Clin Genet, 91, pp.881~891 (2017)
- Yum SW, "Diverse trafficking abnormalities of connexin32 mutants causing CMTX", Neurobiol Dis, 11, pp.43~52 (2002)
- Sargiannidou I, "Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects", J Neurosci, 29, pp.4736~4749 (2009)
- Scherer SS, "Connexin32-null mice develop demyelinating peripheral neuropathy", Glia, 24, pp.8~20 (1998)
- Liang GS, "Severe neuropathy with leaky connexin32 hemichannels", Ann Neurol, 57, pp.749~754 (2005)
- Kleopa KA, "Cellular mechanisms of connexin32mutations associated with CNS manifestations", J Neurosci Res, 68, pp.522~534 (2002)
- Choi BO, "Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients", Hum Mutat, 24, pp.185~186 (2004)
- Okamoto T, "Connexin32 is expressed in vascular endothelial cells and participates in gap-junction intercellular communication", Biochem Biophys Res Commun, 382, pp.264~268 (2009)
- Okamoto T, "Connexin32 protects against vascular inflammation by modulating inflammatory cytokine expression by endothelial cells", Exp Cell Res, 317, pp.348~355 (2011)
- Ginsberg L, "Coexistent hereditary and inflammatory neuropathy", Brain, 127(Pt 1), pp.193~202 (2004)
- Sallusto F, "T-cell trafficking in the central nervous system", Immunol Rev, 248, pp.216~227 (2012)